Patient Portal

Brad S. Kahl, MD

Professor, Medicine
Division of Oncology

Director, Lymphoma Program

Specialty Areas

Lymphoma
Leukemia
Hematologic Malignancies

Board Certifications

Internal Medicine
Hematology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Lymphoma, CLL

  • Location(s)
  • Education
  • Publication & Research
  • Financial Disclosures

Location(s)

Location(s)

Siteman Cancer Center - South County

5225 MidAmerica Plaza
St. Louis, MO 63129

Office Phone: 314-747-7222

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Office Phone: 314-747-7222

Education

Education

Fellowship, Hematology: University of Wisconsin-Madison, Madison, WI 2000
Chief Medical Resident: University of Wisconsin-Madison, Madison, WI 1998
Residency, Internal Medicine: University of Wisconsin-Madison, Madison, WI 1997
Medical Degree: Tufts University School of Medicine, Boston, MA 1994
Bachelor of Science: University of Wisconsin-Madison, Madison, WI 1989

Publication & Research

Publication & Research

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.
Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM
Acta Haematol. 2019 Jul 17; 1-11. doi: 10.1159/000500666.

PMID:
    31315113
    [PubMed - as supplied by publisher]
Related citations


Course of platelet miRNAs after cessation of P2Y12 antagonists.
Jäger B, Stojkovic S, Haller PM, Piackova E, Kahl BS, Andric T, Vargas KG, Wojta J, Huber K
Eur J Clin Invest. 2019 Aug; 49(8)e13149. doi: 10.1111/eci.13149.

PMID:
    31172515
    [PubMed - in process]
Related citations


Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP
J Clin Oncol. 2019 Jul 20; 37(21)1790-1799. doi: 10.1200/JCO.18.01994.

PMID:
    30939090
    [PubMed - in process]
Related citations


Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW
Blood. 2019 Apr 18; 133(16)1762-1765. doi: 10.1182/blood-2018-08-870915.

PMID:
    30723079
    [PubMed - in process]
Related citations


Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.
Kahl BS, Dreyling M, Gordon LI, Martin P, Quintanilla-Martinez L, Sotomayor EM
Leuk Lymphoma. 2019 Aug; 60(8)1853-1865. doi: 10.1080/10428194.2019.1571205.

PMID:
    30696305
    [PubMed - in process]
Related citations


The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR, COMPLETE Investigators.
Cancer. 2019 May 1; 125(9)1507-1517. doi: 10.1002/cncr.31861.

PMID:
    30694529
    [PubMed - in process]
Related citations


NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.
Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H
J Natl Compr Canc Netw. 2019 Jan; 17(1)12-20. doi: 10.6004/jnccn.2019.0002.

PMID:
    30659125
    [PubMed - in process]
Related citations


Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.
Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Leonard JP, Fisher RI, Friedberg JW, Stiff PJ
Leuk Lymphoma. 2019 Aug; 60(8)1934-1941. doi: 10.1080/10428194.2018.1563691.

PMID:
    30628511
    [PubMed - in process]
Related citations


Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS
Br J Haematol. 2019 Feb; 184(4)524-535. doi: 10.1111/bjh.15720.

PMID:
    30575016
    [PubMed - in process]
Related citations


Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas Into Effective New Therapies?
Landsburg DJ, Kahl BS
Clin Lymphoma Myeloma Leuk. 2019 Feb; 19(2)65-67. doi: 10.1016/j.clml.2018.11.017.

PMID:
    30555036
    [PubMed - in process]
Related citations


Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma.
Kahl BS
Clin Adv Hematol Oncol. 2018 Nov; 16(11)732-734.

PMID:
    30543588
    [PubMed - indexed for MEDLINE]
Related citations


Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
O'Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, Jones J, Burger J, Jain N, Allen K, Faia K, Douglas M, Stern HM, Sweeney J, Kelly P, Kelly V, Flinn I
Am J Hematol. 2018 Nov; 93(11)1318-1326. doi: 10.1002/ajh.25243.

PMID:
    30094870
    [PubMed - indexed for MEDLINE]
Related citations


CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL
Blood. 2018 Sep 6; 132(10)1013-1021. doi: 10.1182/blood-2018-01-827246.

PMID:
    30049811
    [PubMed - indexed for MEDLINE]
Related citations


Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era.
King RL, Nowakowski GS, Witzig TE, Scott DW, Little RF, Hong F, Gascoyne RD, Kahl BS, Macon WR
Blood Cancer J. 2018 Feb 28; 8(3)27. doi: 10.1038/s41408-018-0064-9.

PMID:
    29531316
    [PubMed - indexed for MEDLINE]
Related citations


High-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements with diffuse large B-cell lymphoma morphology.
Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A
Blood. 2018 May 3; 131(18)2060-2064. doi: 10.1182/blood-2017-12-820605.

PMID:
    29475959
    [PubMed - indexed for MEDLINE]
Related citations


Follicular lymphoma: are we ready for a risk-adapted approach?
Kahl BS
Hematology Am Soc Hematol Educ Program. 2017 Dec 8; 2017(1)358-364. doi: 10.1182/asheducation-2017.1.358.

PMID:
    29222279
    [PubMed - indexed for MEDLINE]
Related citations


VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Chang JE, Carmichael LL, Kim K, Peterson C, Yang DT, Traynor AM, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS
Clin Lymphoma Myeloma Leuk. 2018 Jan; 18(1)e61-e67. doi: 10.1016/j.clml.2017.10.006.

PMID:
    29191715
    [PubMed - indexed for MEDLINE]
Related citations


NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells.
Li Y, Wang F, Lu L, Zhu F, Huang S, Nomie K, Zhang L, Yang DT, Huang W, Kahl BS, Safe S, Wang M, Rui L
Blood Cancer J. 2017 Nov 23; 7(12)632. doi: 10.1038/s41408-017-0005-z.

PMID:
    29167454
    [PubMed - indexed for MEDLINE]
Related citations


Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H
J Natl Compr Canc Netw. 2017 Nov; 15(11)1414-1427. doi: 10.6004/jnccn.2017.0165.

PMID:
    29118233
    [PubMed - indexed for MEDLINE]
Related citations


Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.
Henderson TO, Parsons SK, Wroblewski KE, Chen L, Hong F, Smith SM, McNeer JL, Advani RH, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard JI, Kahl BS, Kelly KM, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM
Cancer. 2018 Jan 1; 124(1)136-144. doi: 10.1002/cncr.30979.

PMID:
    28902390
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2018:

Company Name: Legal Firm-Irell / Genentech

Royalties:

Equity: No

Consulting/Advisory Board: $20,000 - $39,999

Speaker Fees:

Reporting Date: May 01, 2019

Areas of Research Interest

Developing new and better treatment approaches to lymphoma and chronic lymphocytic leukemia.